Search results

Janssen is one of the world's leading companies in the research and development of innovative medicines. As part of the Johnson & Johnson healthcare group, we focus on some of the greatest medical challenges of our time.

LaRive Bio is a clinical development and licensing organization founded in 2021 and based in Zug. We seek to identify, license in/acquire, develop and license out molecules in areas of significant unmet medical need, applying an abbreviated regulatory pathway. At present, focus lies on neurology.

MphaR is a company providing a full range of services in the area of Medical Affairs in Oncology, Neurology and Rare Disease TA. We assist clients who develop innovative therapies. As a digital solution for the pharmaceutical industry, MphaR offers Virtual Advisory Board Platform.

Micreos is a platform biotech company focused on discovering and developing recombinant proteins for chronic dermatology, oncology, and respiratory conditions.

OCCIDENT invests in deep tech start-ups focusing on spin-offs from scientific research that address societal challenges. As an owner-managed venture capital investor, we support life sciences and industrial tech start-ups from the seed stage onwards, investing own money long-term.

orgart is a company builder for future healthcare business. We have strong ties to investors, experts, and a deep understanding of technology-driven healthcare. We support ventures to achieve their visions, investors to invest in winners, and established corporations to grow in future markets.

Phoenixus AG is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs.

Primex Pharmaceuticals is a leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.

Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).

Since 2007, Rapid Pharma Development provides CMC Services for emerging pharmaceutical companies. As architects in drug development, we built your GMP clinical supply chain, and IMPD dossiers, with the support of reliable outsourcing contract research, and manufacturing organizations.

Founded in 2006, Redalpine is a leading European Venture Capital investor based in Switzerland with offices in Zurich and Berlin. The fund has more than CHF 1bn in Assets under Management and invests in ICT and Life Sciences, with a highly disciplined and sector-agnostic approach.

At RGCC, we are at the forefront of revolutionizing healthcare through personalized solutions for cancer and chronic diseases. Our commitment is global, aiming to provide personalised, diagnostic and therapeutic options to patients worldwide.​

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.

sfm is the leading partner for the development and production of single use medical devices and pharma applicators. The special quality of our integrated solutions primarily results from an intensive dialogue with our customers and an in-depth understanding of their requirements.

Swixx represents the portfolio of biopharma multinationals in markets they choose not to enter or exit.  We are present in 50+ countries in Central and Eastern Europe, MENA, Eurasia/CIS and LATAM. With >2,000 employees, Swixx is one of the largest commercialization platforms for biopharma companies.

Vitaris supplies microbiology and cell culture labs with high-quality devices and consumables. The general laboratory range offers products for varied solutions for users in the life science industry. Thanks to our own service department we are able to ensure the longevity of your acquisitions.